Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 26.77M 24.7M 22.35M 41.8M 2.85B 42.47M 295M 118M 1.49B 112M 110M 4.72B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.77M 9.94M 8.99M 16.81M 1.15B 17.09M 119M 47.29M 599M 45.13M 44.17M 1.9B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
Oct. 28 BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2026 CI
Oct. 23 Briacell Therapeutics Corp. Announces Clinical Biomarker Findings from Prospective Pooled Analysis of Patients with Metastatic Breast Cancer Treated with Immune Based Therapies Including the Briacell Regimen CI
Sep. 14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
Sep. 11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
Sep. 08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
Sep. 01 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Aug. 24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
Aug. 05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
Aug. 05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
1 day-4.32%
1 week-3.93%
Current month-23.77%
1 month-19.83%
3 months-3.73%
6 months-15.45%
Current year-52.55%
1 week 4.64
Extreme 4.64
5.1
1 month 4.64
Extreme 4.64
6.15
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
18
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-4.32%-3.93%-73.28%-99.45% 30.12M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-1.17%+26.27%+55.26% 45.99B
-0.48%-2.80%+18.01%+99.11% 42.45B
+0.82%+1.37%+227.94%+936.89% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.77%+3.01%+39.80%+136.78% 39.26B
Weighted average by Cap. -0.11%+3.13%+49.44%+160.60%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.29M -3.96M -3.58M -6.7M -456M -6.81M -47.24M -18.84M -239M -17.98M -17.6M -756M -26.31M -23.57M -21.74M -19.68M -36.79M -2.51B -37.39M -259M -103M -1.31B -98.75M -96.64M -4.15B
Net Debt -862K -772K -712K -645K -1.21M -82.09M -1.22M -8.5M -3.39M -42.96M -3.24M -3.17M -136M -17.87M -16M -14.76M -13.36M -24.98M -1.7B -25.39M -176M -70.27M -890M -67.05M -65.62M -2.82B
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-10-29 CA$4.650 -4.32% 7,126
26-10-28 CA$4.860 -2.99% 2,012
26-10-27 CA$5.010 +2.87% 4,150
26-10-26 CA$4.870 +1.67% 4,182
26-10-23 CA$4.790 -1.03% 1,187

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.